Abstract
Clinical efficacy of Malaseb™ containing 2% miconazole nitrate and 2% chlorhexidine gluconate in topical management of Malassezia dermatitis was evaluated in a randomized, investigator-blinded, 1% selenium disulfide shampoo-controlled trial. One hundred twenty six dogs with Malassezia dermatitis were divided into Malaseb™ and control using a random number table. Skin lesions including erythema, scales, seborrhea and pruritus were scored before and after the trial by the investigators. Culture tests were performed before and after the trial as the evaluation of Staphylococcus spp. and Malassezia spp. Total score and all skin lesion’s score after the trial showed significantly lower levels than before the trial (P≤0.001). Total score after the trial in Malaseb™ revealed significantly lower level than control (P≤0.001). Two groups after the trial had significantly low counts of Staphylococcus spp. and Malassezia spp., and did not show significantly difference. However, Malaseb™ revealed lower counts of Staphylococcus spp. and Malassezia spp. than control. Malaseb™ had 7.1% adverse effects with mild symptoms, and two groups did not show significantly differences of adverse effects (P=0.718). Based on these results, it is indicated that Malaseb™ is an effective and safe topical therapy in dogs with Malassezia dermatitis.
